A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

Study Summary

The purpose of this study is to assess the efficacy, antitumor activity, safety and tolerability of selinexor plus low-dose dexamethasone in participants with penta-refractory multiple myeloma or selinexor and bortezomib plus low-dose dexamethasone in participants with triple-class refractory multiple myeloma.

Conditions

Multiple Myeloma, Refractory

Interventions / Drugs

Selinexor Dexamethasone Bortezomib

View on ClinicalTrials.gov ↗

Sponsor

KPTI

Karyopharm Therapeutics

Oncology

D40/100

Study Details

Enrollment127 participants

Primary Completion—

Lead SponsorKaryopharm Therapeutics Inc

Data Retrieved2026-04-11 04:19:01.923369+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.